Výsledky vyhľadávania - "Sever, Peter"

Amiloride: A review Autor Sun, Qianhui, Sever, Peter

“…Amiloride is a potassium retaining diuretic and natriuretic which acts by reversibly blocking luminal epithelial sodium channels (ENaCs) in the late distal…”
Získať plný text

Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension Autor Rothwell, Peter M, Howard, Sally C, Dolan, Eamon, O'Brien, Eoin, Dobson, Joanna E, Dahlöf, Bjorn, Sever, Peter S, Poulter, Neil R

“…The mechanisms by which hypertension causes vascular events are unclear. Guidelines for diagnosis and treatment focus only on underlying mean blood pressure…”
Získať plný text

Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial Autor Charytan, David M, Sabatine, Marc S, Pedersen, Terje R, Im, KyungAh, Park, Jeong-Gun, Pineda, Armando Lira, Wasserman, Scott M, Deedwania, Prakash, Olsson, Anders G, Sever, Peter S, Keech, Anthony C, Giugliano, Robert P

“…Data on PCSK9 inhibition in chronic kidney disease (CKD) is limited. The purpose of this study was to compare outcomes with evolocumab and placebo according to…”
Zistit podrobnosti o prístupe

Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk) Autor Bonaca, Marc P, Nault, Patrice, Giugliano, Robert P, Keech, Anthony C, Pineda, Armando Lira, Kanevsky, Estella, Kuder, Julia, Murphy, Sabina A, Jukema, J Wouter, Lewis, Basil S, Tokgozoglu, Lale, Somaratne, Ransi, Sever, Peter S, Pedersen, Terje R, Sabatine, Marc S

“…The PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor evolocumab reduced low-density lipoprotein cholesterol and cardiovascular events in the…”
Zistit podrobnosti o prístupe

Cognitive Function in a Randomized Trial of Evolocumab Autor Giugliano, Robert P, Mach, François, Zavitz, Kenton, Kurtz, Christopher, Im, Kyungah, Kanevsky, Estella, Schneider, Jingjing, Wang, Huei, Keech, Anthony, Pedersen, Terje R, Sabatine, Marc S, Sever, Peter S, Robinson, Jennifer G, Honarpour, Narimon, Wasserman, Scott M, Ott, Brian R

“…To address concerns about cognitive decline with the use of PCSK9 inhibitors, automated neuropsychological testing was performed in patients who received…”
Získať plný text

Inflammatory and Cholesterol Risk in the FOURIER Trial Autor Bohula, Erin A, Giugliano, Robert P, Leiter, Lawrence A, Verma, Subodh, Park, Jeong-Gun, Sever, Peter S, Lira Pineda, Armando, Honarpour, Narimon, Wang, Huei, Murphy, Sabina A, Keech, Anthony, Pedersen, Terje R, Sabatine, Marc S

“…In the FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Patients With Elevated Risk), the PCSK9 (proprotein convertase…”
Zistit podrobnosti o prístupe

Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase Autor Gupta, Ajay, Thompson, David, Whitehouse, Andrew, Collier, Tim, Dahlof, Bjorn, Poulter, Neil, Collins, Rory, Sever, Peter

“…In blinded randomised controlled trials, statin therapy has been associated with few adverse events (AEs). By contrast, in observational studies, larger…”
Získať plný text

Association of Nonfasting vs Fasting Lipid Levels With Risk of Major Coronary Events in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm Autor Mora, Samia, Chang, C Lan, Moorthy, M Vinayaga, Sever, Peter S

“…Recent guidelines have recommended nonfasting for routine testing of lipid levels based on comparisons of nonfasting and fasting populations. However, no…”
Zistit podrobnosti o prístupe

Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis Autor Giugliano, Robert P, Pedersen, Terje R, Saver, Jeffrey L, Sever, Peter S, Keech, Anthony C, Bohula, Erin A, Murphy, Sabina A, Wasserman, Scott M, Honarpour, Narimon, Wang, Huei, Lira Pineda, Armando, Sabatine, Marc S

“…Background and Purpose- The PCSK9 (proprotein convertase subtilisin-kexin type 9) monoclonal antibody evolocumab lowered LDL (low-density lipoprotein)…”
Zistit podrobnosti o prístupe

Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial Autor Giugliano, Robert P, Pedersen, Terje R, Park, Jeong-Gun, De Ferrari, Gaetano M, Gaciong, Zbigniew A, Ceska, Richard, Toth, Kalman, Gouni-Berthold, Ioanna, Lopez-Miranda, Jose, Schiele, François, Mach, François, Ott, Brian R, Kanevsky, Estella, Pineda, Armando Lira, Somaratne, Ransi, Wasserman, Scott M, Keech, Anthony C, Sever, Peter S, Sabatine, Marc S

“…LDL cholesterol is a well established risk factor for atherosclerotic cardiovascular disease. How much one should or safely can lower this risk factor remains…”
Získať plný text

Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score: Results From the FOURIER Trial Autor Marston, Nicholas A, Kamanu, Frederick K, Nordio, Francesco, Gurmu, Yared, Roselli, Carolina, Sever, Peter S, Pedersen, Terje R, Keech, Anthony C, Wang, Huei, Lira Pineda, Armando, Giugliano, Robert P, Lubitz, Steven A, Ellinor, Patrick T, Sabatine, Marc S, Ruff, Christian T

“…The ability of a genetic risk score to predict risk in established cardiovascular disease and identify individuals who derive greater benefit from PCSK9…”
Zistit podrobnosti o prístupe

Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial Autor Sabatine, Marc S., Giugliano, Robert P., Keech, Anthony, Honarpour, Narimon, Wang, Huei, Liu, Thomas, Wasserman, Scott M., Scott, Robert, Sever, Peter S., Pedersen, Terje R.

“…Despite current therapies, patients with vascular disease remain at high risk for major adverse cardiovascular events. Low-density lipoprotein cholesterol is a…”
Získať plný text

Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIER Autor Sabatine, Marc S, De Ferrari, Gaetano M, Giugliano, Robert P, Huber, Kurt, Lewis, Basil S, Ferreira, Jorge, Kuder, Julia F, Murphy, Sabina A, Wiviott, Stephen D, Kurtz, Christopher E, Honarpour, Narimon, Keech, Anthony C, Sever, Peter S, Pedersen, Terje R

“…The FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Patients With Elevated Risk) recently showed that the PCSK9 (proprotein…”
Zistit podrobnosti o prístupe

Interpretation of the evidence for the efficacy and safety of statin therapy Autor Collins, Rory, Reith, Christina, Emberson, Jonathan, Armitage, Jane, Baigent, Colin, Blackwell, Lisa, Blumenthal, Roger, Danesh, John, Smith, George Davey, DeMets, David, Evans, Stephen, Law, Malcolm, MacMahon, Stephen, Martin, Seth, Neal, Bruce, Poulter, Neil, Preiss, David, Ridker, Paul, Roberts, Ian, Rodgers, Anthony, Sandercock, Peter, Schulz, Kenneth, Sever, Peter, Simes, John, Smeeth, Liam, Wald, Nicholas, Yusuf, Salim, Peto, Richard

“…This Review is intended to help clinicians, patients, and the public make informed decisions about statin therapy for the prevention of heart attacks and…”
Získať plný text

Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial Autor Williams, Bryan, MacDonald, Thomas M, Morant, Steve, Webb, David J, Sever, Peter, McInnes, Gordon, Ford, Ian, Cruickshank, J Kennedy, Caulfield, Mark J, Salsbury, Jackie, Mackenzie, Isla, Padmanabhan, Sandosh, Brown, Morris J

“…Optimal drug treatment for patients with resistant hypertension is undefined. We aimed to test the hypotheses that resistant hypertension is most often caused…”
Získať plný text

Effects of β blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke Autor Rothwell, Peter M, Howard, Sally C, Dolan, Eamon, O'Brien, Eoin, Dobson, Joanna E, Dahlöf, Bjorn, Poulter, Neil R, Sever, Peter S

“…Analyses of some randomised trials show that calcium-channel blockers reduce the risk of stroke more than expected on the basis of mean blood pressure alone…”
Získať plný text

Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial Autor Sabatine, Marc S, Leiter, Lawrence A, Wiviott, Stephen D, Giugliano, Robert P, Deedwania, Prakash, De Ferrari, Gaetano M, Murphy, Sabina A, Kuder, Julia F, Gouni-Berthold, Ioanna, Lewis, Basil S, Handelsman, Yehuda, Pineda, Armando Lira, Honarpour, Narimon, Keech, Anthony C, Sever, Peter S, Pedersen, Terje R

“…The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab reduced LDL cholesterol and cardiovascular events in the FOURIER trial. In this…”
Zistit podrobnosti o prístupe

The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism Autor Marston, Nicholas A, Gurmu, Yared, Melloni, Giorgio E M, Bonaca, Marc, Gencer, Baris, Sever, Peter S, Pedersen, Terje R, Keech, Anthony C, Roselli, Carolina, Lubitz, Steven A, Ellinor, Patrick T, O'Donoghue, Michelle L, Giugliano, Robert P, Ruff, Christian T, Sabatine, Marc S

“…The relationship between cholesterol levels and risk of venous thromboembolism (VTE) is uncertain. We set out to determine the effect of PCSK9 (proprotein…”
Zistit podrobnosti o prístupe

Side Effect Patterns in a Crossover Trial of Statin, Placebo, and No Treatment Autor Howard, James P, Wood, Frances A, Finegold, Judith A, Nowbar, Alexandra N, Thompson, David M, Arnold, Ahran D, Rajkumar, Christopher A, Connolly, Susan, Cegla, Jaimini, Stride, Chris, Sever, Peter, Norton, Christine, Thom, Simon A M, Shun-Shin, Matthew J, Francis, Darrel P

“…Most people who begin statins abandon them, most commonly because of side effects. The purpose of this study was to assess daily symptom scores on statin,…”
Zistit podrobnosti o prístupe

Nocebo affects after COVID-19 vaccination Autor Sever, Professor Peter

Získať plný text